Balyasny Asset Management’s NovoCure NVCR Stock Holding History

Balyasny Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65,000	Closed	-$1.05M	–	2774
2023 Q3	$1.05M	Sell	65,000 -325,000	-83%	-$9.37M	﹤0.01%	1555
2023 Q2	$16.2M	Buy	390,000 +325,000	+500%	+$20.2M	0.04%	603
2023 Q1	$3.91M	Buy	+65,000	New	+$5.19M	0.01%	1179
2022 Q3	–	Sell	-23,800	Closed	-$1.65M	–	3142
2022 Q2	$1.65M	Hold	23,800	–	–	0.01%	1507
2022 Q1	$1.97M	Buy	+23,800	New	+$1.75M	0.01%	1361

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Balyasny Asset Management's NVCR Position: Q1 2026 in Review

Balyasny Asset Management reduced its NovoCure (NVCR) stake by 62% in Q1 2026, selling an estimated $244K and leaving 11,831 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Balyasny Asset Management first reported a position in NVCR in Q1 2018 and has held it in 21 quarters since. The position peaked at $40.4M in Q2 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Balyasny Asset Management held 11,831 shares of NovoCure worth $129K as of Q1 2026.
Balyasny Asset Management sold 19,508 NovoCure shares in Q1 2026, an estimated $244K.
NovoCure made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2744 holding.
Balyasny Asset Management first reported a position in NovoCure in Q1 2018 and has held it in 21 quarters since.
Balyasny Asset Management's NovoCure position peaked at $40.4M in Q2 2025.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.